Abstract
Cervical dystonia (CD) causes involuntary muscle spasms and is often associated with pain. Recently, botulinum toxin type B (BTX-B) (Myobloc™, Elan South San Francisco, CA, USA) was approved for general use in the treatment of CD in the USA. In two large pivotal trials, BTX-B was found to be safe and effective in decreasing the movements, pain and disability associated with CD. Benefits were noted both in patients who no longer respond and in those who continue to respond to botulinum toxin type A (BTX-A). BTX-B offers an additional therapeutic option for patients with CD.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2191-2199 |
| Number of pages | 9 |
| Journal | Expert Opinion on Investigational Drugs |
| Volume | 10 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 31 2001 |
| Externally published | Yes |
Fingerprint
Keywords
- Botulinum toxin
- Cervical dystonia
- Chemodenervation
- Myobloc™
- NeuroBloc®
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
Botulinum toxin type B : A new injectable treatment for cervical dystonia. / Brashear, A.
In: Expert Opinion on Investigational Drugs, Vol. 10, No. 12, 31.12.2001, p. 2191-2199.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Botulinum toxin type B
T2 - A new injectable treatment for cervical dystonia
AU - Brashear, A.
PY - 2001/12/31
Y1 - 2001/12/31
N2 - Cervical dystonia (CD) causes involuntary muscle spasms and is often associated with pain. Recently, botulinum toxin type B (BTX-B) (Myobloc™, Elan South San Francisco, CA, USA) was approved for general use in the treatment of CD in the USA. In two large pivotal trials, BTX-B was found to be safe and effective in decreasing the movements, pain and disability associated with CD. Benefits were noted both in patients who no longer respond and in those who continue to respond to botulinum toxin type A (BTX-A). BTX-B offers an additional therapeutic option for patients with CD.
AB - Cervical dystonia (CD) causes involuntary muscle spasms and is often associated with pain. Recently, botulinum toxin type B (BTX-B) (Myobloc™, Elan South San Francisco, CA, USA) was approved for general use in the treatment of CD in the USA. In two large pivotal trials, BTX-B was found to be safe and effective in decreasing the movements, pain and disability associated with CD. Benefits were noted both in patients who no longer respond and in those who continue to respond to botulinum toxin type A (BTX-A). BTX-B offers an additional therapeutic option for patients with CD.
KW - Botulinum toxin
KW - Cervical dystonia
KW - Chemodenervation
KW - Myobloc™
KW - NeuroBloc®
UR - http://www.scopus.com/inward/record.url?scp=0035215847&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035215847&partnerID=8YFLogxK
U2 - 10.1517/13543784.10.12.2191
DO - 10.1517/13543784.10.12.2191
M3 - Article
C2 - 11772315
AN - SCOPUS:0035215847
VL - 10
SP - 2191
EP - 2199
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
SN - 1354-3784
IS - 12
ER -